This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

A Few Minutes With Chelsea's CEO on Tuesday's Northera Panel and Future Plans

By: Adam Feuerstein | 01/17/14 - 10:33 AM EST

Stocks in this article: CHTP

I spoke briefly with Chelsea Therapeutics'  (CHTP) CEO Joe Olivetto this morning about Tuesday's positive Northera FDA advisory panel and next steps for the company.

For those who missed it, the FDA panel voted 16-1 to recommend the approval of Northera for the treatment of neurogenic orthostatic hypotension (NOH), a chronic disease characterized by dangerously low blood pressure.

The FDA approval decision date for Northera is Feb. 14. FDA rejected Northera following a positive panel vote in 2012, so there are no guarantees. However, I believe it will be much more difficult for FDA to reject Northera again. Two positive panels following a very thorough presentation and discussion of all the issues with the Northera clinical data justifies an FDA approval.

That's how I see it.

Anyway, back to Olivetti's comments from our quick chat this morning.

His reaction to Tuesday's panel:

I was very happy with the outcome. Even with the vote being dramatically positive, you still worry about mis-understandings. Did the panelists get it? Did they understand the issues? Was the vote based on mis-perceptions? I don't think we saw any of that. The panelists did a great job. They were prepared and they dove right in.

On the company's strategy going into the panel and why the panelists votes to recommend Northera's approval:

We had been discussing the issues about Northera with the FDA for awhile so there were no surprises. We were prepared to discuss the issues and articulate them as clearly as we could. And the panelists were also really prepared....

The key was in the second half of the day, emphasizing the unmet medical need [for NOH.] This is not a disease that causes a little dizziness. It is a complicated disease that really affects peoples' lives. And it's a disease that is really hard to study... Our experts did a great job. We also had something like 18 people testify [during the open public hearing], including 10 NOH patients who talked about their experience with the disease and taking Northera.

On his prediction on the FDA's upcoming approval decision:

We feel good about Northera going into the PDUFA date. I think the FDA got good advice from the panel that they can take back with them and use to weigh in on their final decision.

On what the Northera label might look like, assuming FDA approval:

Part will depend on whether FDA grants Northera full approval or approval based on subpart H [accelerated approval], which would come with a requirement for a follow-through trial.

There could be a range of labels. The worst possible label would include a contra indication saying that Northera is not to be used after 1-2 weeks. Now, I don't know of any drug that has that kind of label, except maybe for safety reasons, so I think there is low chance for this to happen with Northera.

Other label possibilities might have FDA include a statement saying Northera has not been proven to show a durable response beyond 1-2 weeks, or the agency could put the clinical data in the label, showing that response wasn't statistically significant after 1-2 weeks.

If the FDA includes language in the Northera label about the benefit of the drug lasting only 1-2 weeks, will this have an effect on how insurance companies reimburse for the drug?

This is a relatively new issue, so I could only really speculate at this time. We need to study it but I'm sure this will be a question investors will ask.

On the timeline for a Northera commercial launch, again, assuming FDA approves the drug on Feb. 14:

We're looking at about a six-month timeline between final approval and launch... We have all our marketing plans in place from last time and we believe they are still good... We'll be using a contract sales organization [to sell Northera] so they will have to be hired. And production of Northera will need to be teed up, which will start on approval.



Shares of Chelsea have been volatile, particularly as doubts about the panel outcome took hold in the past few weeks. But the stock rallied nicely after the positive vote on Tuesday:
CHTP Chart
CHTP data by YCharts

Back to my take: I like Chelsea and believe the stock has more upside following approval. There's a chance FDA delays a decision by three months since the agency only has one month to digest the recommendations of the panel and nail down the Northera label. But as one smart analyst said to me Tuesday night (we were talking about the panel), a short delay in Northera's approval for what are basically administrative reasons could actually be a benefit to Chelsea and the net present value of Northera since the commercial launch and drug manufacturing still need to be nailed down.


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs